Compare CR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CR | BIO |
|---|---|---|
| Founded | 1855 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Metal Fabrications | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 7.1B |
| IPO Year | 2022 | N/A |
| Metric | CR | BIO |
|---|---|---|
| Price | $174.37 | $273.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $223.40 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 304.2K | 241.3K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | ★ 23.96 | N/A |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $2,305,000,000.00 | N/A |
| Revenue This Year | $28.11 | $2.74 |
| Revenue Next Year | $5.76 | $3.05 |
| P/E Ratio | $27.64 | ★ $9.72 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $127.04 | $211.43 |
| 52 Week High | $214.31 | $343.12 |
| Indicator | CR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 48.84 |
| Support Level | N/A | $266.71 |
| Resistance Level | $187.13 | $289.61 |
| Average True Range (ATR) | 5.91 | 7.69 |
| MACD | -1.13 | 1.39 |
| Stochastic Oscillator | 27.54 | 78.70 |
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.